CBIZ Investment Advisory Services LLC Raises Stock Holdings in Bristol Myers Squibb Company $BMY

CBIZ Investment Advisory Services LLC raised its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 66.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 581 shares of the biopharmaceutical company’s stock after acquiring an additional 231 shares during the period. CBIZ Investment Advisory Services LLC’s holdings in Bristol Myers Squibb were worth $35,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of the company. Modern Wealth Management LLC raised its holdings in shares of Bristol Myers Squibb by 16.5% during the 1st quarter. Modern Wealth Management LLC now owns 18,426 shares of the biopharmaceutical company’s stock worth $1,124,000 after acquiring an additional 2,608 shares in the last quarter. Silicon Valley Capital Partners increased its position in shares of Bristol Myers Squibb by 49.2% during the 1st quarter. Silicon Valley Capital Partners now owns 1,053 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 347 shares during the last quarter. Strs Ohio bought a new position in shares of Bristol Myers Squibb during the 1st quarter valued at approximately $36,305,000. Intrua Financial LLC increased its position in shares of Bristol Myers Squibb by 25.9% during the 1st quarter. Intrua Financial LLC now owns 22,616 shares of the biopharmaceutical company’s stock valued at $1,379,000 after purchasing an additional 4,652 shares during the last quarter. Finally, Advisors Capital Management LLC increased its position in shares of Bristol Myers Squibb by 4.3% during the 1st quarter. Advisors Capital Management LLC now owns 812,837 shares of the biopharmaceutical company’s stock valued at $49,575,000 after purchasing an additional 33,874 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares of the company’s stock, valued at approximately $7,922,048.07. This represents a 25.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.09% of the company’s stock.

Bristol Myers Squibb Stock Performance

Shares of Bristol Myers Squibb stock opened at $47.52 on Friday. The stock’s fifty day moving average is $47.09 and its two-hundred day moving average is $50.26. The company has a market capitalization of $96.72 billion, a PE ratio of 19.16, a price-to-earnings-growth ratio of 2.41 and a beta of 0.35. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. Bristol Myers Squibb Company has a 52 week low of $42.96 and a 52 week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating the consensus estimate of $1.07 by $0.39. The company had revenue of $12.27 billion for the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.Bristol Myers Squibb’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd were given a dividend of $0.62 per share. The ex-dividend date of this dividend was Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.2%. Bristol Myers Squibb’s dividend payout ratio is presently 100.00%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on BMY shares. Daiwa Capital Markets downgraded Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 target price on the stock. in a research report on Tuesday, August 5th. Citigroup cut their target price on Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating on the stock in a research report on Friday, August 1st. Daiwa America downgraded Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 5th. Wall Street Zen downgraded Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 6th. Finally, Morgan Stanley reissued a “hold” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $56.38.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.